Large Cap Pharma Stocks – Large Cap Pharma Stocks List

The table below shows the Large Cap Pharma Stocks based on the Highest Market Capitalization.

Content: 

• What Are Pharma Stocks?
• Large Cap Pharma Stocks In India
• Large Cap Pharma Stocks List
• Best Large Cap Pharma Stocks
• Top Large Cap Pharma Stocks In India
• Who Should Invest In Large Cap Pharma Stocks?
• How To Invest In The Large Cap Pharma Stocks?
• Performance Metrics Of Large Cap Pharma Stocks In India
• Benefits Of Investing In Large Cap Pharma Stocks
• Challenges Of Investing In Large Cap Pharma Stocks
• Introduction To Best Large Cap Pharma Stocks
• Top Large Cap Pharma Stocks In India – FAQs

What Are Pharma Stocks?

Pharma stocks refer to publicly traded companies involved in the research, development, manufacturing, and commercialization of pharmaceutical products, including prescription drugs, over-the-counter medications, vaccines, and biotechnology-based therapies. These stocks are part of the healthcare sector and are subject to regulatory oversight and market dynamics.

Large Cap Pharma Stocks In India

The table below shows the Large Cap Pharma Stocks In India based on 1 Year Return. 

Large Cap Pharma Stocks List

The table below shows the Large Cap Pharma Stocks List based on the highest day Volume.

Best Large Cap Pharma Stocks

The table below shows the Best Large Cap Pharma Stocks based on the PE Ratio. 

Top Large Cap Pharma Stocks In India

The table below shows the Top Large Cap Pharma Stocks In India based on the 6-month return. 

Who Should Invest In Large Cap Pharma Stocks?

Investing in large-cap pharmaceutical stocks involves researching companies like Lupin Ltd, Dr Reddy’s Laboratories Ltd, and Laurus Labs Ltd. Evaluate their financial health, pipeline of drugs, patents, and market presence. Consider factors like regulatory approvals, competition, and industry trends. Diversify your portfolio to spread risk. Monitor news, earnings reports, and industry developments regularly. Consult financial advisors or do thorough research before making investment decisions.

How To Invest In The Large Cap Pharma Stocks?

To invest in large-cap pharma stocks, you typically need to open an account with a stockbroker. Choose a reputable broker with a user-friendly trading platform and competitive commission rates. Once your account is set up, you can research and select specific pharma stocks to buy, and then place orders through your broker’s platform.

Performance Metrics Of Large Cap Pharma Stocks In India

The performance metrics of large-cap pharma stocks include evaluating the company’s market share in key therapeutic areas to determine its competitive standing within the industry. This assessment helps understand how well the company performs against its competitors in significant segments.

1. Revenue Growth: Track the year-over-year revenue growth to assess the company’s ability to generate sales and expand its market presence.

2. Earnings Per Share (EPS): Evaluate the company’s profitability by analyzing its EPS growth over time.

3. Price-to-Earnings (P/E) Ratio: Compare the company’s stock price to its earnings per share to determine its valuation relative to its peers and the market.

4. Dividend Yield: Consider the dividend yield offered by the stock, indicating the percentage of dividends paid relative to its current market price.

5. Return on Equity (ROE): Measure the company’s efficiency in generating profits from shareholders’ equity.

6. Debt-to-Equity Ratio: Assess the company’s financial leverage by comparing its debt to its equity, indicating its ability to manage debt obligations.

Benefits Of Investing In Large Cap Pharma Stocks

The main benefits of investing in large-cap pharma stocks include substantial investments in research and development, resulting in a strong pipeline of potential blockbuster drugs. These innovations can significantly drive future growth and revenue for these companies.

1. Stability: Large-cap pharmaceutical companies often have established products, diversified revenue streams, and global operations, providing stability during market fluctuations.

2. Dividend Income: Many large-cap pharma stocks offer dividends, providing a regular income stream for investors, especially those seeking income-oriented investments.

3. Defensive Qualities: The healthcare sector, including pharmaceuticals, is considered defensive, as demand for essential medications tends to remain stable even during economic downturns.

4. Growth Potential: Despite their size, large-cap pharmaceutical companies continue to innovate and develop new drugs, offering long-term growth potential as they capitalize on healthcare advancements.

5. Global Reach: Large-cap pharma companies often have a global presence, allowing investors to benefit from revenue generated across multiple markets and currencies.

6. Regulatory Protection: Regulatory barriers to entry in the pharmaceutical industry provide a level of protection for established companies, reducing competition and enhancing their market position.

Challenges Of Investing In Large Cap Pharma Stocks

The main challenges of investing in large-cap pharma stocks include competition from generic drug manufacturers, biotechnology firms, and emerging market players. This competition can result in market share erosion and pricing pressures, impacting these companies’ profitability and growth potential.

1. Patent Expirations: Many blockbuster drugs have finite patent protection, leading to the risk of generic competition upon expiration, which can significantly impact revenue and profitability.

2. Regulatory Risks: Large-cap pharma companies are subject to stringent regulatory oversight, including drug approvals, manufacturing standards, and pricing regulations, which can affect product launches and profitability.

3. Research and Development Costs: Developing new drugs is expensive and time-consuming, with no guarantee of success. High R&D costs can impact profitability, especially if promising drug candidates fail in clinical trials.

4. Pricing Pressures: Healthcare reforms, payer negotiations, and public scrutiny often lead to pricing pressures on pharmaceutical products, impacting revenue and profitability margins.

5. Pipeline Uncertainty: The success of large-cap pharmaceutical companies heavily relies on the performance of their drug pipelines. Setbacks in clinical trials or failures to bring new drugs to market can adversely affect stock performance.

6. Litigation Risks: Pharmaceutical companies may face legal challenges related to patent infringement, product liability claims, or regulatory violations, leading to financial penalties and reputational damage.

7. Currency Fluctuations: Global operations expose large-cap pharmaceutical companies to currency exchange rate risks, impacting revenue and profitability when translating foreign earnings into their reporting currency.

Introduction To Best Large Cap Pharma Stocks

Large Cap Pharma Stocks – Highest Market Capitalization

Sun Pharmaceutical Industries Ltd

The Market Cap of Sun Pharmaceutical Industries Ltd is Rs 367434.16 crore. The stock’s monthly return is -0.17%. Its one-year return is 63.62%. The stock is 7.02% away from its 52-week high.

Sun Pharmaceutical Industries Limited, an Indian-based pharmaceutical company specializing in generic medications, is involved in the manufacturing, developing, and marketing of a diverse range of branded and generic pharmaceutical formulations and active ingredients. The company offers a broad portfolio of generic and specialty medicines for chronic and acute medical conditions. With a vertically integrated network, Sun Pharma can produce a wide array of pharmaceutical products, including oncology drugs, hormones, peptides, and steroidal medications. 

Additionally, the company is in international markets, offering products such as injectables, hospital medications, and retail items. Sun Pharma provides a range of dosage forms, including oral medications, creams, ointments, injectables, sprays, and liquid formulations. Its specialty product lineup includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, Yonsa, Sezaby, and the Sprinkle portfolio.

Cipla Ltd

The Market Cap of Cipla Ltd is Rs. 112,958.59 crore. The stock’s monthly return is 3.27%. Its one-year return is 51.42%. The stock is 8.57% away from its 52-week high.

Cipla Limited, headquartered in India, is a pharmaceutical company primarily involved in the development, manufacturing, and distribution of generic and branded medications through its two operating segments: Pharmaceuticals and New ventures. 

The Pharmaceuticals segment focuses on producing and selling generic or branded generic drugs, as well as Active Pharmaceutical Ingredients (API). The New ventures segment encompasses consumer healthcare, Biosimilars, and specialty products. Cipla’s product portfolio includes a range of medications such as complex generics for respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system (CNS) conditions. The company’s operations span India, the United States, South Africa, and other global regions.  

Zydus Lifesciences Ltd

The Market Cap of Zydus Lifesciences Ltd is Rs. 105795.44 crores. The stock’s monthly return is 5.98%. Its one-year return is 94.49%. The stock is 0.54% away from its 52-week high.

Zydus Lifesciences Ltd. is an Indian company that focuses on life sciences. The company is involved in various activities such as research, development, manufacturing, marketing, and selling of a range of products. This includes finished dosage human formulations like generics and specialty formulations, as well as biosimilars and vaccines, active pharmaceutical ingredients (APIs), animal healthcare products, and consumer wellness products. 

Some of its notable products are Bilypsa (saroglitizar), Oxemia (desidustat), Ujvira (a biosimilar to Kadcyla), and Exemptia. Bilypsa targets non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), while Desidustat is used for treating anemia in chronic kidney disease patients. The company is also working on ZYIL1 to address inflammation caused by the NLRP3 inflammasome and has developed ZyCoV-D, a DNA vaccine for dealing with COVID-19.

Large Cap Pharma Stocks In India – 1-Year Return

Lupin Ltd

The Market Cap of Lupin Ltd is Rs. 75,278.52 crores. The stock’s monthly return is 2.36%. Its one-year return is 111.51%. The stock is 3.18% away from its 52-week high.

Lupin Limited, an India-based pharmaceutical company, focuses on producing, developing, and marketing a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. The company operates in various therapeutic segments such as Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives, Nonsteroidal Anti Inflammatory Drug therapy, Anti-TB, and Cephalosporins. Lupin Limited and its subsidiaries cater to a diverse market with manufacturing facilities in India, the United States, Mexico, and Brazil and global trading activities. 

Their product portfolio includes complex generics like Filgrastim, Pegfilgrastim, Etanercept, and Albuterol. Additionally, they offer biosimilar products such as Lupifil (Filgrastim), Lupifil-P (Peg-Filgrastim), Etanercept, and diabetes brands like ONDERO and ONDERO MET.

IPCA Laboratories Ltd

The Market Cap of IPCA Laboratories Ltd is Rs. 33,024.68 crore. The stock’s monthly return is -4.63%. Its one-year return is 90.33%. The stock is 5.60% away from its 52-week high.

IPCA Laboratories Limited, headquartered in India, is a pharmaceutical company that produces and markets more than 350 formulations and about 80 active pharmaceutical ingredients (APIs) for various therapeutic areas. Their range of APIs includes Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. 

Additionally, the company offers a variety of branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, and many more. These products are distributed in over 100 countries worldwide. Ipca Laboratories operates 18 manufacturing facilities in India for both APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., IPCA Laboratories (U.K.) Ltd, and Tonira Exports Limited.

Aurobindo Pharma Ltd

The Market Cap of Aurobindo Pharma Ltd is Rs. 68,264.78 crore. The stock’s monthly return is 4.14%. Its one-year return is 88.03%. The stock is 2.16% away from its 52-week high.

Aurobindo Pharma Limited is an Indian pharmaceutical company that specializes in manufacturing and marketing various pharmaceutical products and services. The company’s product range covers seven therapeutic areas, including the Central Nervous System, Antiretrovirals, Cardiovascular, Oral and Sterile products, Anti-infectives, Anti-diabetics, and Oral Cephalosporins. 

Aurobindo Pharma is also developing oncology and hormonal products and topical and transdermal products in dermatology. They are working on three depot injections using advanced technology platforms. The company sells its products in around 150 countries globally and has subsidiaries such as APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, and APL Pharma Thai Limited.

Large Cap Pharma Stocks List – Highest Day Volume

Mankind Pharma Ltd

The Market Cap of Mankind Pharma Ltd is Rs. 83,749.02 crores. The stock’s monthly return is -8.66%. Its one-year return is 54.36%. The stock is 19.10% away from its 52-week high.

Mankind Pharma Limited is an Indian pharmaceutical company that is involved in the development, production, and promotion of a wide range of pharmaceutical products across various acute and chronic health conditions, as well as consumer healthcare items. The company offers a variety of formulations in therapeutic categories like anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain relief, among others. 

In addition to these, it also operates in fields such as urology, ophthalmology, antiparasitic, stomatology, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sexual health, anti-tuberculosis, parenteral, and vaccine segments. Some of its well-known brands include Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, among others.

GlaxoSmithKline Pharmaceuticals Ltd

The Market Cap of GlaxoSmithKline Pharmaceuticals Ltd is Rs. 38743.16 crores. The stock’s monthly return is 5.80%. Its one-year return is 76.59%. The stock is 10.36% away from its 52-week high.

GlaxoSmithKline Pharmaceuticals Limited, a global healthcare company based in India, manufactures, distributes, and trades pharmaceutical products. The company operates in three main product categories: vaccines, specialty medicines, and general medicines. The general medicines segment offers a range of medications, including anti-infectives, pain relievers, dermatology treatments, and vitamins. Some of its generally well-known drug brands are Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, and Physiogel. 

T-bact products under the brand are specifically designed for bacterial skin infections. In terms of vaccines, the company boasts brands like Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra, and Varilrix. Their specialty medicines division focuses on developing treatments for respiratory issues and HIV, with additional emphasis on expanding into areas like immunology and oncology. Notable specialty medicine brands from GlaxoSmithKline Pharmaceuticals Limited include Nucala and Trelegy Ellipta.

Dr Reddy’s Laboratories Ltd

The Market Cap of Dr Reddy’s Laboratories Ltd is Rs. 96,579.02 crore. The stock’s monthly return is -3.71%. Its one-year return is 29.41%. The stock is 12.18% away from its 52-week high.

Dr. Reddy’s Laboratories Limited is a pharmaceutical company headquartered in India with a global presence. The company provides a range of products and services, which include active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter (OTC) medications. Its key focus areas in terms of therapeutic treatment include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. 

The company is divided into segments, namely Pharmaceutical Services and Active Ingredients, Global Generics, and Others. The Pharmaceutical Services and Active Ingredients segment primarily deals with the manufacturing and marketing of APIs and intermediates. The Global Generics segment focuses on the manufacturing and marketing of prescription and OTC pharmaceutical products for patient consumption, which are sold either under a brand name (branded formulations) or as generic medications with therapeutic equivalence to branded formulations (generics).

Best Large Cap Pharma Stocks – PE Ratio

Gland Pharma Ltd

The Market Cap of Gland Pharma Ltd is Rs. 29503.77 crores. The stock’s monthly return is 1.37%. Its one-year return is 33.81%. The stock is 22.48% away from its 52-week high.

Gland Pharma Limited is a company based in India that specializes in generic injectables. They focus on producing complex injectables and operate within the sterile injectables, oncology, and ophthalmology sectors. The company offers contract and in-house development, dossier preparation and filing, technology transfer, and manufacturing for different delivery systems. Their products are available in various forms, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. 

Some of the key products they offer include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection. The company’s therapeutic product categories cover a wide range including Anti Malarials, Anti-Infectives, Anti-Neoplastics, Blood Related, Cardiac, Gastrointestinal, Gynaecological, Hormones, Neuro / CNS, Ophthal / Otologicals, Pain/Analgesics, Respiratory, and Vitamins / Minerals / Nutrients. Their products are distributed in various countries, including the United States, Europe, Canada, and other regions.

Top Large Cap Pharma Stocks In India – 6 Month Return

Glenmark Pharmaceuticals Ltd

The Market Cap of Glenmark Pharmaceuticals Ltd amounts to Rs. 28,770.49 crore. The monthly return rate stands at -5.23%, whereas the one-year return rate is 67.46%. The stock currently sits at 7.69% below its 52-week high.

Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, is dedicated to establishing a strong presence in the global pharmaceutical market by focusing on branded, generic, and over-the-counter (OTC) products in dermatology, respiratory, and oncology. The company also operates in regional and country-specific markets, offering products in areas such as diabetes, cardiovascular health, and oral contraceptives. 

Glenmark’s diverse product line includes topical treatments, liquids, respiratory inhalers, injectables, biologics, and oral medications. In the United Kingdom and Spain, the company markets Tiogiva and Tavulus, respectively, which are bioequivalent versions of Tiotropium Bromide dry powder inhaler (DPI) used in treating chronic obstructive pulmonary disease. Additionally, Ryaltris is Glenmark’s first globally branded specialty product, a nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for the treatment of allergic rhinitis.

J B Chemicals and Pharmaceuticals Ltd

The Market Cap of J B Chemicals and Pharmaceuticals Ltd is Rs. 28,323.05 crore. The stock’s monthly return is 2.31%. Its one-year return is 84.96%. The stock is 6.30% away from its 52-week high.

J. B. Chemicals & Pharmaceuticals Limited is an Indian pharmaceutical company that specializes in manufacturing and marketing a variety of pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (APIs). The company’s product range covers various therapeutic categories including gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance. 

They offer a diverse selection of lozenges, including center-filled soft-centered, powder-filled, herbal, and medicated varieties. Additionally, the company provides a comprehensive line of diagnostic imaging products such as X-ray, MRI, and ultrasound contrast media both domestically and internationally. Their product portfolio includes tablets, capsules, liquids, IV infusions, ampoules, vials, ointments, cold rubs, lozenges, and sips. Some of their well-known brands include Rantac OD, RD, Ranraft, Metrogyl ER, Metrogyl O, Nicardia XL, Sporlac EVA, and Sporlac G.

Top Large Cap Pharma Stocks In India – FAQs

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.